Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The primary endpoint is freedom from serious adverse events (SAE), defined as death, symptomatic pulmonary embolism or major bleeding .
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Embolism Deep Vein Thrombosis Venous Thromboembolism |
Device: Angel Catheter Placement |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism |
- Safety [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]The primary endpoint is freedom from serious adverse events (SAE), defined as death, symptomatic pulmonary embolism or major bleeding . The other primary safety endpoint are freedom from vena cava thrombosis, vena cava perforation, filter migration, insertion vein thrombosis and catheter related blood infection prolonging hospitalization and requiring IV antibiotics.
- Angel Catheter Functional Assessment [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]The secondary study endpoints are insertion and retrieval of the inferior vena cava (IVC) filter without the occurrence of adverse events. Evaluation of the function of the multi-lumen catheter in terms of infusion rates of medications and fluids, blood sampling, occlusion of the infusion lumens and monitoring of the central venous pressure.
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | August 2012 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Angel Catheter |
Device: Angel Catheter Placement
The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is 18 years and older
Be admitted to the hospital
One of the following two criteria:
Patients with proven DVT or PE, at high risk for pulmonary embolism and under consideration for insertion of a retrievable IVC filter with at least one of the following criteria:
- Contraindications for anticoagulation
- Recurrent PE despite adequate anticoagulation
- Emergency treatment following massive pulmonary embolism
Patients at high risk for developing PE who require but have a temporary or absolute contraindication for prophylaxis with anticoagulation, including:
- Patients with multiple trauma and active or recent bleeding with contraindications to anticoagulation or that require a temporary stop of anticoagulation
- severe head injury with coma
- severe hemorrhagic stroke with coma
- head injury with a long bone fracture
- spinal cord injury with paraplegia or quadriplegia
- multiple (≥2) long bone fractures with pelvic fracture
- multiple (≥4) long bone fractures
- Critically ill patients in the Medical or Surgical Intensive Care Unit with high risk of PE that require but are contraindicated for anticoagulation prophylaxis and will benefit from a temporary filter and a central venous access catheter
- Patients who had recently undergone or are about to undergo a surgical procedure that requires temporary interruption of anticoagulation for VTE and will benefit from a temporary vena cava filter and central
Exclusion Criteria:
- Patient is less than 18 years
- Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG) pregnancy test at baseline visit
- Patient or next legal representative cannot give informed consent
- Patients with anticipated survival < 2 days (catastrophic illness)
- Body mass index greater than 35
- Patient has a pre-existing filter
- Participation in another simultaneous interventional medical investigation or interventional trial.
- Patient has indications for a permanent filter at the time of the initial evaluation
- Patient has an uncontrollable coagulopathy with active bleeding.
- Patient with proven endocarditis or bacteremia
- Patient has hypersensitivity to any of the components of the Angel™ Catheter, specifically Nitinol
- Known acute or chronic thrombotic occlusion of both common femoral veins or iliac veins
- Patient with functioning pelvic renal allograft on the only side available for device insertion
- Patient who will undergo surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted
Contacts and Locations| Contact: Luis F Angel, MD | 210-213-9778 | langel@bio2medical.com |
| Colombia | |
| Clinica las Americas | Not yet recruiting |
| Medellin, Antioquia, Colombia | |
| Contact: Bladimir Gil, MD 574-341-6060 ext UCI bladigil@yahoo.com | |
| Principal Investigator: Bladimir Gil, MD | |
| Hospital Pablo Tobon Uribe | Not yet recruiting |
| Medellin, Antioquia, Colombia | |
| Contact: Carlos Cadavid, MD 574-445-9000 ext UCI ccadavid@hptu.org.co | |
| Principal Investigator: Carlos Cadavid, MD | |
| Principal Investigator: | Carlos Cadavid, MD | Hospital Pablo Tobon Uribe |
| Principal Investigator: | Bladimir Gil, MD | Clinica Las Americas |
More Information
No publications provided
| Responsible Party: | Luis F. Angel MD, BiO2 Medical |
| ClinicalTrials.gov Identifier: | NCT01403090 History of Changes |
| Other Study ID Numbers: | CPR-001 |
| Study First Received: | July 25, 2011 |
| Last Updated: | July 26, 2011 |
| Health Authority: | Colombia: National institute of Vigilance of Medications and Food (INVIMA) |
Keywords provided by BiO2 Medical:
|
Pulmonary Embolism Deep Vein Thrombosis Venous Thromboembolism Central Line Catheter Vena Cava Filters |
Additional relevant MeSH terms:
|
Pulmonary Embolism Embolism Thromboembolism Thrombosis Venous Thrombosis Venous Thromboembolism |
Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 16, 2013